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The medial temporal lobe (MTL) has long
been identified as a key region affected
by neurodegenerative diseases, a common
source of cognitive decline in the elderly.
The importance of the MTL with respect
to cognitive decline is furthered by the hip-
pocampus’s role in memory formation (1).
Impairment of declarative memory is one
of the earliest symptoms of Alzheimer’s
disease (AD), the most common form of
dementia. Early involvement of the MTL
in AD is characterized by the presence
of neurofibrillary tangles in the entorhi-
nal cortex. As the disease progresses, neu-
rofibrillary tangles continue to accumu-
late and involve the hippocampus, amyg-
dala, and ultimately the neocortex (2). This
gradual progression mirrors the worsen-
ing symptoms patients with AD experi-
ence. While initial concerns include mem-
ory deterioration, patients in later stages
of AD can present with progressive apha-
sia (3), visuospatial impairments including
agnosia (4), and apraxia (5).
Neuroimaging findings from
Alzheimer’s patients are consistent with
the pathologic and clinical pattern, sug-
gesting potential clinical diagnostic use.
Structural magnetic resonance (MR) imag-
ing analysis of patients with mild cognitive
impairment (MCI) and AD is most notable
for MTL atrophy, including significant
volume reduction in the hippocampus,
amygdala, parahippocampal gyrus, and
entorhinal cortex (6). Structural MRI has
identified the entorhinal cortex as the first
region to display atrophy in AD. Atrophy
in this region is followed by atrophy in
the hippocampus, amygdala, and parahip-
pocampal gyrus (7). The next region to
display atrophy includes the posterior cin-
gulate cortex; the atrophy then becomes
generalized to the temporal neocortex and
neocortical association areas (8). Thus,
the evolution of neuroimaging findings
on MRI closely mirrors the progression of
neurodegenerative pathology, suggesting
that volume assessment by MRI may be a
useful clinical tool for early diagnosis and
disease monitoring.
Qualitative visual assessment of tem-
poral lobe atrophy on MRI has demon-
strated a sensitivity of approximately 80%
in distinguishing AD from normal aging,
depression, and vascular dementia (9). A
recent study revealed that qualitative visual
assessment of MTL atrophy differentiated
pathologically confirmed AD from vas-
cular cognitive impairment and demen-
tia with Lewy bodies with a sensitivity of
91% and specificity of 94% (10). Atro-
phy of the MTL is particularly important
because it can be detected earlier than
generalized whole brain atrophy in AD.
Unfortunately, there is significant varia-
tion in qualitative assessment of MTL atro-
phy among radiologists. One investiga-
tion of cognitively normal elderly individ-
uals revealed a 70% interobserver agree-
ment (kappa values of 0.59 and 0.62) in
identifying the presence of MTL atrophy
on coronal T1-weighted MRI scans (11).
Another study included elderly patients
with dementia and the interobserver agree-
ment dropped to 49.7%, with kappa values
of 0.34 and 0.24 (12). Such poor inter-rater
reliability is a major limitation for imple-
menting qualitative MTL atrophy assess-
ments in a clinical setting on individual
patients.
This limitation has been addressed by
quantitative volumetric analysis of MTL
structures, which offers improved reliabil-
ity and predictive accuracy. A comparison
of qualitative ratings of MTL atrophy and
hippocampal volumetry revealed that vol-
umetry was more accurate in predicting
cognitive decline to AD in MCI patients
(100 vs. 78% positive predictive value, 100
vs. 87% negative predictive value) (13).
A challenge of using any MTL atrophy
assessment is that these structures often
display volume loss in cognitively normal
patients, much of which is attributed to
the normal aging process. However, the
effect of AD on MTL atrophy is much
greater. Even patients with mild AD dis-
play significantly greater volume loss in
MTL structures when compared to cog-
nitively normal controls (14). The specific
structure within the MTL that has demon-
strated the most accuracy in predicting
the presence of AD is the hippocampus.
A semi-automated tracing-threshold tech-
nique for segmenting the hippocampus
yielded a sensitivity of 82% and speci-
ficity of 80% in identifying patients with
AD as compared to controls (14). Serial
volume measurements tracking hippocam-
pal change over time show even greater
effects compared to baseline values alone.
Rates of hippocampal atrophy were found
to be considerably greater in Alzheimer’s
patients (−3.98%, −150 mm3/year) as
compared to control patients (−1.55%,
−75 mm3/year) (15). Additionally, hip-
pocampal atrophy rates were found to cor-
relate with patients’ baseline cognitive sta-
tuses and also matched cognitive decline,
with atrophy rates increasing from controls
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FIGURE 1 | Patient is an 85-year-old female with a 3-year history of
memory loss with differential diagnosis of normal aging vs. mild
Alzheimer’s disease vs. vascular dementia. Figure demonstrates
morphometry results displaying axial, coronal, and sagittal color-segmented
images of the brain as well as volumetrics expressed in absolute and
normalized units. Graphs demonstrate normalized volumes plotted against
percentiles for age for the hippocampi and temporal horns. Results
demonstrate hippocampal volume below the 5th percentile and temporal
horns above the 95th percentile, supporting provisional diagnosis of mild
Alzheimer’s disease.
(1.73% for stable, 2.81% for decliners) to
MCI (2.55% for stable, 3.69% for decliners)
to AD (3.5%) (16).
While studies have established this clear
finding of hippocampal atrophy in AD,hip-
pocampal volumetry has not yet become
a routine part of the diagnostic work-up
for neurodegenerative diseases. Volumet-
ric calculations required time-consuming,
labor-intensive manual tracing over the
borders of MTL structures over multiple
slices. Summed regions of interest over the
slices are used to count the number of
voxels and ultimately produce a volume
measurement. Despite the advantages over
visual ratings, this method requires indi-
vidual segmentation of structures within
the MTL which may also vary consider-
ably across different operators, depend-
ing upon their training and experience.
Moreover, it is unclear how to account
for the aging process and differences in
head size in interpretation of such volume
measurements in individual patients.
These concerns have been addressed
through the development of software pro-
grams such as FreeSurfer, Individual Brain
Atlases using statistical parametric map-
ping (IBASPM), and NeuroQuant that
allow for completely automated, user-
independent calculations of neural vol-
umes. NeuroQuant, a commercial imple-
mentation of the FreeSurfer algorithm, also
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generates an age-related atrophy percentile,
in addition to a general morphometry
report (Figure 1). The age-related atrophy
report includes the volume, percentage of
intracranial volume, and normative per-
centiles for the hippocampus, lateral ven-
tricles, and inferior lateral ventricles (tem-
poral horns). The normative percentiles are
based on control subjects from the mul-
ticenter AD Neuroimaging Initiative data-
base (17). Implementations of these pro-
grams operate without user input and allow
for rapid volumetric calculation and report
generation immediately after a patient’s
MRI scan has been obtained, making them
well-suited for incorporation into a busy
clinical workflow.
Several of these software packages
have been validated in studies compar-
ing Alzheimer’s patients to cognitively nor-
mal controls. Volumetric analysis was per-
formed in both groups of patients using
NeuroQuant vs. semi-manual segmenta-
tion as a gold standard. There was a high
degree of agreement in the volumes gen-
erated (hippocampus, ICC= 0.93, inferior
lateral ventricle, ICC= 0.92). Both meth-
ods demonstrated volume loss of the hip-
pocampus and associated increased infe-
rior lateral ventricle size in Alzheimer’s
patients as compared to controls (18).
FreeSurfer has also been incorporated in
assessment of temporal lobe structures in
patients with AD and semantic dementia.
One investigation revealed that FreeSurfer
correlated highly with manual volumetric
delineation, particularly in the ventricles
(r = 0.99), right medial-inferior tempo-
ral gyrus (r = 0.84), and left hippocampus
(r = 0.76) (19).
Further investigations are needed to
elucidate the clinical role and utility of
automated hippocampal volumetry. While
studies have demonstrated the sensitivity
of hippocampal and MTL atrophy for con-
ditions such as MCI and AD, hippocam-
pal atrophy can occur in a number of
other settings. Hippocampal atrophy has
been documented in numerous conditions
ranging from Cushing’s syndrome, major
depression, posttraumatic stress disorder
(20), Type 2 Diabetes (21), traumatic brain
injury, and concussions (22). Research has
also implicated several genotypes associ-
ated with hippocampal volumes. Val66Met
polymorphisms of the BDNF gene have
been linked to worsened episodic memory
(23) and reduced hippocampal volumes
(24), suggesting BDNF’s role in vulnerabil-
ity to neural changes associated with aging
(25). The APOE ε4 allele has also demon-
strated an association with increased rate
(26) and amount (27) of hippocampal
atrophy. Decreased hippocampal volumes
in patients with depression were linked to
44-base pair insertions in the promoter
region of the serotonin transporter (5-
HTTLPR) (28). Therefore, additional work
is needed to establish the specificity of
hippocampal atrophy in a general prac-
tice setting, including patients with multi-
ple, sometimes coexisting, conditions, and
genotypes.
In addition, while we believe hippocam-
pal volumetry can be incorporated into
neuroimaging evaluation of patients with
potential neurodegenerative diseases, sig-
nificant work still needs to be done to estab-
lish standardized volumetry thresholds for
atrophy rates and age-adjusted volumes
that will be useful in practice for different
clinical contexts, such as differential diag-
nosis, early identification/prediction, and
disease monitoring. A clear delineation of
hippocampal boundaries is required along
with a standardized, accessible database,
and uniform methods of reporting hip-
pocampal volumes (29). Hippocampal vol-
umetry still awaits U.S. FDA approval for
specific clinical contexts of use because
of the current lack of standardized vol-
umetry norms. Nevertheless, the European
Medicines Agency has approved the use
of this technique for sample enrichment
in clinical trials (30). Though full incor-
poration in routine practice awaits such
norms, complete hierarchical validation
(31) may unnecessarily delay implemen-
tation; therefore, alternative approaches
should be considered for concurrent assess-
ment and implementation of this technol-
ogy (32). Hippocampal volumetrics may
currently be helpful as an aid in differential
diagnosis of dementia and MCI in spe-
cific cases, particularly when values fall in
the normal range. Hippocampal volume-
try may be particularly important in iden-
tifying patients in the pre-clinical stages
of AD and also in predicting worsening
of MCI patients. Indeed, new diagnos-
tic criteria have been proposed for both
AD and MCI due to AD which incorpo-
rate MRI volumetry as a neuronal loss
marker (33). Thus, the time is now for
hippocampal volumetry to become a com-
ponent of the neuroimaging evaluation of
patients with suspected neurodegenerative
disease.
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